FMN2 is a novel regulator of the cyclin-dependent kinase inhibitor p21

被引:13
|
作者
Yamada, Kayo [1 ]
Ono, Motoharu [1 ]
Bensaddek, Dalila [1 ]
Lamond, Angus I. [1 ]
Rocha, Sonia [1 ]
机构
[1] Univ Dundee, Ctr Gene Regulat & Express, Coll Life Sci, Dundee, Scotland
基金
英国惠康基金;
关键词
DNA damage; FMN2; cancer; cell cycle; hypoxia; p14ARF; p21; p53; ARF TUMOR-SUPPRESSOR; NF-KAPPA-B; P53; TRANSACTIVATION; IDENTIFICATION; DEGRADATION; NETWORKS; REVEALS; CANCER; ATR;
D O I
10.4161/cc.25511
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We have identified the human FMN2 gene as a novel target regulated by induction of p14ARF and by multiple other stress responses, including DNA damage and hypoxia, which have in common activation of cell cycle arrest. We showed that increased expression of the FMN2 gene following p14ARF induction is caused, at the transcriptional level, by relief of repression by RelA and E2F1, which, under non-induced conditions, bind the FMN2 promoter. Increased FMN2 protein levels promote cell cycle arrest by inhibiting the degradation of p21, and our data show that control of p21 stability is a key part of the mechanism that regulates p21 induction. Consistent with this model, we have shown that transient expression of exogenous FMN2 protein alone is sufficient to increase p21 protein levels in cells, without altering p21 mRNA levels. Here, we provide additional evidence for the role of the N terminus of FMN2 as being the important domain required for p21 stability. In addition, we also investigate the role of RelA's threonine 505 residue in the control of FMN2. Our results identify FMN2 as a crucial protein involved in the control of p21.
引用
收藏
页码:2348 / 2354
页数:7
相关论文
共 50 条
  • [21] A MUTANT P21 CYCLIN-DEPENDENT KINASE INHIBITOR ISOLATED FROM A BURKITTS-LYMPHOMA
    BHATIA, K
    FAN, SJ
    SPANGLER, G
    WEINTRAUB, M
    OCONNOR, PM
    JUDDE, JG
    MAGRATH, I
    CANCER RESEARCH, 1995, 55 (07) : 1431 - 1435
  • [22] Direct interaction of p21 cyclin-dependent kinase inhibitor with the retinoblastoma tumor suppressor protein
    Nakanishi, M
    Kaneko, Y
    Matsushime, H
    Ikeda, K
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 263 (01) : 35 - 40
  • [23] Cyclin-dependent kinase inhibitor p21 does not impact embryonic endochondral ossification in mice
    Chinzei, Nobuaki
    Hayashi, Shinya
    Hashimoto, Shingo
    Kanzaki, Noriyuki
    Iwasa, Kenjiro
    Sakata, Shuhei
    Kihara, Shinsuke
    Fujishiro, Takaaki
    Kuroda, Ryosuke
    Kurosaka, Masahiro
    MOLECULAR MEDICINE REPORTS, 2015, 11 (03) : 1601 - 1608
  • [24] INHIBITION OF CYCLIN-DEPENDENT KINASES BY P21
    HARPER, JW
    ELLEDGE, SJ
    KEYOMARSI, K
    DYNLACHT, B
    TSAI, LH
    ZHANG, PM
    DOBROWOLSKI, S
    BAI, C
    CONNELLCROWLEY, L
    SWINDELL, E
    FOX, MP
    WEI, N
    MOLECULAR BIOLOGY OF THE CELL, 1995, 6 (04) : 387 - 400
  • [25] P53-INDEPENDENT EXPRESSION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P21 IN PANCREATIC-CARCINOMA
    DIGIUSEPPE, JA
    REDSTON, MS
    YEO, CJ
    KERN, SE
    HRUBAN, RH
    AMERICAN JOURNAL OF PATHOLOGY, 1995, 147 (04): : 884 - 888
  • [26] CELL-CYCLE EXPRESSION AND P53 REGULATION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P21
    LI, Y
    JENKINS, CW
    NICHOLS, MA
    XIONG, Y
    ONCOGENE, 1994, 9 (08) : 2261 - 2268
  • [27] Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex
    Waga, S
    Stillman, B
    MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (07) : 4177 - 4187
  • [28] Cyclin-Dependent Kinase Inhibitor 1a (p21) Modulates Response to Cocaine and Motivated Behaviors
    Scholpa, Natalie E.
    Briggs, Sherri B.
    Wagner, John J.
    Cummings, Brian S.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 357 (01): : 56 - 65
  • [29] IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells
    Amy C Hobeika
    Prem S Subramaniam
    Howard M Johnson
    Oncogene, 1997, 14 : 1165 - 1170
  • [30] Induction of terminal differentiation in kidney tubules by the p21 cyclin-dependent kinase (cdk) inhibitor.
    Price, PM
    Megyesi, J
    Udvarhelyi, N
    Safirstein, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A1770 - A1770